In Australia, high-contact sports, like football, rugby and such, have some of the highest head injury rates in the world. There’s an average of five injuries per team per season, no matter how intense the competition. To add to that, whether these head injuries lead to concussions cannot be ascertained instantly. Symptoms might take anywhere
Read More
Beyond the thrilling game, the lively ambience, and the excited spectators, sports always carry risk of injuries for the athletes that should not be overlooked. As a solution, HITIQ (ASX: HIQ) has been striving to minimise head injuries on athletes through its transformative concussion management technology. Most recently, HITIQ has been appointed to exclusively manage
Read More
As the debate over concussions in sport rages across the professional level, it’s flow on impact at the community level is one that sports tech company HITIQ (ASX: HIQ) foresees in the immediate future, as they set to increase their retail sales exposure through a collaboration with mouthguards manufacturer Shock Doctor. Those of us that
Read More
As one of the world’s highest contact team sports, American Football has had a nasty history of concussions that don’t see its deadliest effects until the post-playing phase of careers but with a focus to maximise player lifetime welfare, six leading US Colleges have signed up to sportstech company HitIQ’s (ASX: HIQ) concussion analytics. The
Read More
Injury is inevitable in both elite and recreational sport. Most cuts, bruises, strains and tears can be remedied in a relatively short time frame with minimal ongoing issues. Traumatic brain injuries are quite the opposite. They can be debilitating, life altering and career ending. Following increased researcher interest and the findings of multiple studies, the
Read More
As part of their plans to collaborate with the NRL on concussion solutions, Impression Healthcare (ASX: IHL) has appointed NRL star James Graham to its advisory board to assist with the development of their medicinal cannabis products. In particular, Graham will offer advice on ‘real world’ aspects of the clinical program for IHL-216A, a cannabinoid
Read More